A Phase II, Prospective, Randomized, Double-Blind, Multi-center, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Daxibotulinumtoxin A (Primary)
- Indications Plantar fasciitis
- Focus Therapeutic Use
- Sponsors Revance Therapeutics
- 09 Nov 2020 Results presented in the Revance Therapeutics Media Release.
- 09 Nov 2020 Primary endpoint (Change from baseline in the Numeric Pain Rating Scale (NPRS) score) has not been met, according to a Revance Therapeutics media release.
- 26 Jun 2020 Status changed from active, no longer recruiting to completed.